SLSP 05
Alternative Names: SLSP-05Latest Information Update: 25 Jan 2021
At a glance
- Originator Salspera
- Class Antineoplastics; Bacteria; Gene therapies; Immunotherapies; Interleukins
- Mechanism of Action Bacteria replacements; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 20 Jan 2021 SLSP 05 is available for licensing as of 20 Jan 2021. https://www.salspera.com/
- 20 Jan 2021 Preclinical trials in Solid tumours in USA (PO) before January 2021 (Salspera's pipeline, January 2021)